Stephen Halliday is a Respiratory physician affiliated with University of Wisconsin–Madison. OpenAlex indexes 48 publications with 767 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- United TherapeuticsProgram year202561 paymentsResearch$178,746openpaymentsdata.cms.gov ↗
- Boehringer IngelheimProgram year202591 paymentsResearch$144,935openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
55.4%Kinase inhibitor36.5%Ofev100%Part D<11 patientsPyridone18.9%Pirfenidone100%Part D<11 patientsMetabolism & gastrointestinal
24.3%Corticosteroid24.3%Prednisone100%Part D≥12 patientsAnti-infectives
20.3%Macrolide Antimicrobial20.3%Azithromycin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial
American Journal of Respiratory and Critical Care Medicine
2026 - Variation in SNX29 and Acute Vasodilator Response in Pulmonary Arterial Hypertension
Circulation Research
2026 - A43-03 “Identical” But Different; Twin Brothers With Different Presentations of Familial Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine
2026 - Gastroesophageal Reflux, Sleep‐Disordered Breathing, and Outcomes in Patients With Idiopathic Pulmonary Fibrosis
Canadian Respiratory Journal
2025 - 1074: RISK OF DIFFICULT INTUBATION IN CRITICALLY ILL ADULTS WITH DIABETES MELLITUS
Critical Care Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Lucey, MD
University of Wisconsin–Madison
Paul Rutecki, MD
University of Wisconsin–Madison
Justine Bruce, MD
University of Wisconsin–Madison
Mark Albertini, MD
University of Wisconsin–Madison
Fernando Martinez, MD
University of Massachusetts Chan Medical School
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”